Credit: Getty Images Study supports the role of PSMA PET for risk stratifying patients with clinically node-positive disease before radical prostatectomy, along with mpMRI and clinical parameters.

The percentage of prostate cancer patients with positive lymph nodes increased from 2.4% in 2010 to 4.7% in 2014. The following article is part of conference coverage from the 2018 American Urological ...

In patients with biochemical failure after prostatectomy, about two thirds showed detectable local disease at restaging. Multiparametric MRI alone detected local lesions in over one third of patients ...

Omitting systematic biopsy in men with elevated prostate-specific antigen (PSA) levels and negative MRI results, and performing only targeted biopsy of MRI-positive lesions, eliminated more than half ...

A deep learning model was as effective as radiologists in detecting clinically significant prostate cancer on multiparametric MRI, a retrospective study suggested. In an internal test set of 400 ...

A recent BMJ Oncology study screens the prevalence of prostate magnetic resonance imaging (MRI) lesions in men based on age rather than prostate-specific antigen (PSA) levels. Study: Prevalence of MRI ...

The approval of Posluma will help clinicians determine the extent of disease in men with prostate cancer and possible management options. The Food and Drug Administration (FDA) approved Posluma ...

p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma We evaluated 1,107 patients with pN1 prostate cancer treated ...

Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population-based screening is unknown. We invited 37,887 men who were 50 to 60 years of ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...